Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study.
Adenosine Monophosphate
/ adverse effects
Aged
Aged, 80 and over
Aging
/ physiology
Alanine
/ adverse effects
Antiviral Agents
/ adverse effects
COVID-19
/ mortality
Cohort Studies
Female
Glomerular Filtration Rate
Humans
Male
Retrospective Studies
SARS-CoV-2
Severity of Illness Index
Treatment Outcome
COVID-19 Drug Treatment
SARS CoV2
aging
chronic kidney disease
glomerular filtration rate
remdesivir
Journal
Clinical interventions in aging
ISSN: 1178-1998
Titre abrégé: Clin Interv Aging
Pays: New Zealand
ID NLM: 101273480
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
03
2021
accepted:
14
05
2021
entrez:
11
6
2021
pubmed:
12
6
2021
medline:
23
6
2021
Statut:
epublish
Résumé
Remdesivir, an antiviral agent able to reduce inflammatory cascade accompanying severe, life-threatening pneumonia, became the first drug approved by the Food and Drug Administration for the treatment of hospitalized patients with coronavirus 2 related severe acute respiratory syndrome (SARS CoV2). As from its previously known clinical indications, the use of remdesivir in the presence of severe renal impairment is contraindicated; however, the impact of remdesivir on renal function in aging patients has not been elucidated. This retrospective observational study involved 109 individuals consecutively admitted in internal medicine section, Azienda Ospedaliero Universitaria Pisana hospital, in November-December 2020 due to a confirmed diagnosis of SARS CoV2 and receiving remdesivir according to international inclusion criteria. Biochemical variables at admission were evaluated, together with slopes of estimated glomerular filtration rate (eGFR) built during remdesivir treatment. Participants were followed until discharge or exitus. Patients were stratified according to age (80 formed the study cohort and 29 served as controls); CKD stage III was present in 46% of them. No patients showed any sign of deteriorated renal function during remdesivir. Fourteen patients in the elderly cohort deceased; their eGFR at baseline was significantly lower. Recovered patients were characterized by a relevant eGFR gaining during remdesivir treatment. We show here for the first time as remdesivir does not influence eGFR in a cohort of elderly people hospitalized for SARS CoV2, and that eGFR gain during such treatment is coupled with a better prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
Remdesivir, an antiviral agent able to reduce inflammatory cascade accompanying severe, life-threatening pneumonia, became the first drug approved by the Food and Drug Administration for the treatment of hospitalized patients with coronavirus 2 related severe acute respiratory syndrome (SARS CoV2). As from its previously known clinical indications, the use of remdesivir in the presence of severe renal impairment is contraindicated; however, the impact of remdesivir on renal function in aging patients has not been elucidated.
SUBJECTS AND METHODS
METHODS
This retrospective observational study involved 109 individuals consecutively admitted in internal medicine section, Azienda Ospedaliero Universitaria Pisana hospital, in November-December 2020 due to a confirmed diagnosis of SARS CoV2 and receiving remdesivir according to international inclusion criteria. Biochemical variables at admission were evaluated, together with slopes of estimated glomerular filtration rate (eGFR) built during remdesivir treatment. Participants were followed until discharge or exitus.
RESULTS
RESULTS
Patients were stratified according to age (80 formed the study cohort and 29 served as controls); CKD stage III was present in 46% of them. No patients showed any sign of deteriorated renal function during remdesivir. Fourteen patients in the elderly cohort deceased; their eGFR at baseline was significantly lower. Recovered patients were characterized by a relevant eGFR gaining during remdesivir treatment.
CONCLUSION
CONCLUSIONS
We show here for the first time as remdesivir does not influence eGFR in a cohort of elderly people hospitalized for SARS CoV2, and that eGFR gain during such treatment is coupled with a better prognosis.
Identifiants
pubmed: 34113086
doi: 10.2147/CIA.S313028
pii: 313028
pmc: PMC8184369
doi:
Substances chimiques
Antiviral Agents
0
remdesivir
3QKI37EEHE
Adenosine Monophosphate
415SHH325A
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1037-1046Informations de copyright
© 2021 Biancalana et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Med J Malaysia. 2020 Nov;75(6):710-716
pubmed: 33219182
Open Forum Infect Dis. 2020 Nov 19;7(12):ofaa563
pubmed: 33365358
Life Sci. 2021 Jan 1;264:118663
pubmed: 33121991
Kidney Int. 2016 Feb;89(2):363-73
pubmed: 26509589
Nephron. 2020;144(5):213-221
pubmed: 32203970
Biol Sex Differ. 2021 Feb 5;12(1):20
pubmed: 33546750
Nephrol Ther. 2019 Jul;15(4):220-225
pubmed: 31088765
Eur J Intern Med. 2021 Jan;83:1-5
pubmed: 33303345
Kidney Int. 2020 Jul;98(1):219-227
pubmed: 32327202
J Proteome Res. 2021 Jan 1;20(1):49-59
pubmed: 33347311
Sci Transl Med. 2019 May 29;11(494):
pubmed: 31142680
Nephrology (Carlton). 2017 Sep;22(9):699-705
pubmed: 27312245
Lancet. 2012 Nov 10;380(9854):1662-73
pubmed: 23013602
Kidney Blood Press Res. 2020;45(1):84-94
pubmed: 31794962
J Clin Pharmacol. 2018 Jun;58(6):814-822
pubmed: 29578585
Clin Microbiol Rev. 2020 Oct 14;34(1):
pubmed: 33055231
JAMA. 2020 Sep 15;324(11):1048-1057
pubmed: 32821939
Arch Pathol Lab Med. 2020 Dec 1;144(12):1465-1474
pubmed: 32818235
J Am Soc Nephrol. 2020 Aug;31(8):1683-1687
pubmed: 32371536
Front Endocrinol (Lausanne). 2020 Nov 11;11:557333
pubmed: 33262739
Clin Sci (Lond). 2021 Jan 15;135(1):1-17
pubmed: 33399851
Ann Hepatol. 2017 Oct 16;16(6):851-861
pubmed: 29055921
Ann Intern Med. 2021 May;174(5):663-672
pubmed: 33560863
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
N Engl J Med. 2020 Nov 5;383(19):1827-1837
pubmed: 32459919
Lancet Diabetes Endocrinol. 2015 Jul;3(7):514-25
pubmed: 26028594
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):541-548
pubmed: 33506946
EMBO Mol Med. 2021 Jan 11;13(1):e13105
pubmed: 33015938
BMC Nephrol. 2017 Jun 7;18(1):190
pubmed: 28592280
Crit Care. 2015 Feb 03;19:32
pubmed: 25645660
Ann Intern Med. 2021 Apr;174(4):437-443
pubmed: 33316174
PLoS One. 2021 Jan 5;16(1):e0244779
pubmed: 33400721
Cell Rep. 2020 Jul 21;32(3):107940
pubmed: 32668216
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
BMJ Open. 2021 Jan 11;11(1):e044640
pubmed: 33431495
Am J Infect Control. 2019 Sep;47(9):1140-1145
pubmed: 31003750
JAMA. 2014 Jun 25;311(24):2518-2531
pubmed: 24892770